ArticleSports medicine (Auckland, N.Z.)2026
A Cross-Sectional Survey of Sport Physicians' Perceptions of Glucagon-Like Peptide-1 Drug Use in Sport.
Article in Sports medicine (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAnecdotal evidence suggests glucagon-like peptide-1 (GLP-1) drugs, typically prescribed to manage diabetes mellitus and assist weight loss, are being misused in elite sport. The objective of this study was to investigate sports medicine physicians' perceptions of GLP-1 drug use in sport.
methodsFollowing an observational cross-sectional approach, 114 sports medicine physicians completed a survey addressing experiences and perceptions of GLP-1 use in competitive sport. Participants had worked in sports medicine for 16.6 years on average, 63% were male, and 38 countries and 93 sports were represented. Survey data were analysed using descriptive statistics.
resultsTwelve percent of physicians were aware of athletes who had used GLP-1 drugs without medical need. Physicians most frequently reported that athletes would consider using GLP-1 drugs to meet weight limits and assist weight loss after injury and would be deterred by a lack of energy to train from a reduced appetite. On average, physicians were moderately concerned about the non-prescription use of GLP-1 drugs in sport from a performance enhancement perspective and from an athlete health and welfare perspective. Forty-four percent of participants believed GLP-1 drugs should be prohibited, although 38% reported being unsure. For those supporting prohibition, harm to an athlete's health was the main concern.
conclusionsCurrently, without evidence on the effects of GLP-1 drugs on athletes' health and performance, a proportionate response for sport is education first, structured therapeutic-use pathways, enhanced monitoring, and accelerated sport-specific research including longer-term clinical follow-up of side effects. The approach protects health and fairness, while creating the evidence base needed to judge whether prohibition is justified.
Identifiers
42611174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.